Novel synthetic toll-like receptor 4/MD2 ligands attenuate sterile inflammation

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 2, 2014, Pages 330-340

  Hayashi, Tomoko ^a   Crain, Brian ^a   Yao, Shiyin ^a   Caneda, Christa D ^b   Cottam, Howard B ^a   Chan, Michael ^a   Corr, Maripat ^b   Carson, Dennis A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 Y 82; 1 Z 103; 1 Z 104; 1 Z 105; 1 Z 65; 1 Z 82; 1 Z 88; 247514; 247543; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CD14 ANTIGEN; GALACTOSAMINE; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; HEPATITIS; IMMUNOSTIMULATION; LIVER PROTECTION; LIVER TOXICITY; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; ANTIGENS, CD14; ARTHRITIS, EXPERIMENTAL; GALACTOSAMINE; HEP G2 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLAMMATION; LIGANDS; LYMPHOCYTE ANTIGEN 96; MICE; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 4;

EID: 84905034412     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.214312     Document Type: Article

References (44)

1. Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, van der Meer JW, Netea MG, and van den Berg WB (2007) Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 56:2957-2967.
2. Akashi-Takamura S and Miyake K (2008) TLR accessory molecules. Curr Opin Immunol 20:420-425.
3. Arias MA, Van Roey GA, Tregoning JS, Moutaftsi M, Coler RN, Windish HP, Reed SG, Carter D, and Shattock RJ (2012) Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS ONE 7:e41144.
4. Bao M and Liu YJ (2013) Regulation of TLR7/9 signaling in plasmacytoid dendritic cells. Protein Cell 4:40-52.
5. Barochia A, Solomon S, Cui X, Natanson C, and Eichacker PQ (2011) Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 7:479-494.
6. Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Blüml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, and Planyavsky M, et al. (2010) CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 207:2689-2701.
7. Beutler B (2000) Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol 12:20-26.
8. Casella CR and Mitchell TC (2013) Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A. PLoS ONE 8:e62622.
9. Chan M, Hayashi T, Kuy CS, Gray CS, Wu CC, Corr M, Wrasidlo W, Cottam HB, and Carson DA (2009) Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem 20:1194-1200.
10. Chan M, Hayashi T, Mathewson RD, Nour A, Hayashi Y, Yao S, Tawatao RI, Crain B, Tsigelny IF, and Kouznetsova VL, et al (2013) Identification of substituted pyrimido [5,4-b]indoles as selective Toll-like receptor 4 ligands. J Med Chem 56:4206-4223.
11. Christianson CA, Dumlao DS, Stokes JA, Dennis EA, Svensson CI, Corr M, and Yaksh TL (2011) Spinal TLR4 mediates the transition to a persistent mechanical hyper-sensitivity after the resolution of inflammation in serum-transferred arthritis. Pain 152:2881-2891.
12. Corr M and Crain B (2002) The role of FcgammaR signaling in the K/B x N serum transfer model of arthritis. J Immunol 169:6604-6609.
13. Crozat K, Georgel P, Rutschmann S, Mann N, Du X, Hoebe K, and Beutler B (2006) Analysis of the MCMV resistome by ENU mutagenesis. Mamm Genome 17:398-406.
14. Ditzel HJ (2004) The K/BxN mouse: a model of human inflammatory arthritis. Trends Mol Med 10:40-45.
15. Engelich G, White M, and Hartshorn KL (2001) Neutrophil survival is markedly reduced by incubation with influenza virus and Streptococcus pneumoniae: role of respiratory burst. J Leukoc Biol 69:50-56.
16. Fan H and Cook JA (2004) Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 10:71-84.
17. Fitzgerald KA, Rowe DC, and Golenbock DT (2004) Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect 6:1361-1367.
18. Francis JN and Durham SR (2004) Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 4:543-548.
19. Guma M, Kashiwakura J, Crain B, Kawakami Y, Beutler B, Firestein GS, Kawakami T, Karin M, and Corr M (2010) JNK1 controls mast cell degranulation and IL-1beta production in inflammatory arthritis. Proc Natl Acad Sci USA 107: 22122-22127.
20. Hajjar AM, Ernst RK, Fortuno ES, 3rd, Brasfield AS, Yam CS, Newlon LA, Kollmann TR, Miller SI, and Wilson CB (2012) Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica. PLoS Pathog 8:e1002963.
21. Hayashi T, Gray CS, Chan M, Tawatao RI, Ronacher L, McGargill MA, Datta SK, Carson DA, and Corr M (2009) Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc Natl Acad Sci USA 106:2764-2769.
22. Ishizaka ST and Hawkins LD (2007) E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines 6:773-784.
23. Ismaili J, Rennesson J, Aksoy E, Vekemans J, Vincart B, Amraoui Z, Van Laethem F, Goldman M, and Dubois PM (2002) Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168:926-932.
24. Jiang Z, Georgel P, Du X, Shamel L, Sovath S, Mudd S, Huber M, Kalis C, Keck S, Galanos C, et al. (2005) CD14 is required for MyD88-independent LPS signaling. Nat Immunol 6:565-570.
25. Johnson DA (2008) Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr Top Med Chem 8:64-79.
26. Kerns EH and Di L (2008) Drug-like properties: concepts, structure design and methods: from ADME to toxicity optimization, Academic Press, Amsterdam.
27. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, and Yoo OJ, et al (2007) Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130:906-917.
28. Kobayashi M, Saitoh S, Tanimura N, Takahashi K, Kawasaki K, Nishijima M, Fujimoto Y, Fukase K, Akashi-Takamura S, and Miyake K (2006) Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 176: 6211-6218.
29. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, and Mathis D (1996) Organ-specific disease provoked by systemic autoimmunity. Cell 87:811-822.
30. Lee HK, Dunzendorfer S, Soldau K, and Tobias PS (2006) Double-stranded RNA-mediated TLR3 activation is enhanced by CD14. Immunity 24:153-163.
31. Lu YC, Yeh WC, and Ohashi PS (2008) LPS/TLR4 signal transduction pathway. Cytokine 42:145-151.
32. Mangialaio S, Ji H, Korganow AS, Kouskoff V, Benoist C, and Mathis D (1999) The arthritogenic T cell receptor and its ligand in a model of spontaneous arthritis. Arthritis Rheum 42:2517-2523.
33. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, and Mitchell TC (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316:1628-1632.
34. McAleer JP and Vella AT (2010) Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide. Trends Immunol 31:429-435.
35. Medvedev AE, Sabroe I, Hasday JD, and Vogel SN (2006) Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin Res 12:133-150.
36. Michaud JP, Hallé M, Lampron A, Thériault P, Préfontaine P, Filali M, Tribout-Jover P, Lanteigne AM, Jodoin R, and Cluff C, et al. (2013) Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc Natl Acad Sci USA 110:1941-1946.
37. Moore KJ, Andersson LP, Ingalls RR, Monks BG, Li R, Arnaout MA, Golenbock DT, and Freeman MW (2000) Divergent response to LPS and bacteria in CD14-deficient murine macrophages. J Immunol 165:4272-4280.
38. Ohto U, Fukase K, Miyake K, and Satow Y (2007) Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316:1632-1634.
39. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, and Tidswell M, et al; ACCESS Study Group (2013) Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 309:1154-1162.
40. Park BS, Song DH, Kim HM, Choi BS, Lee H, and Lee JO (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458:1191-1195.
41. Shirey KA, Lai W, Scott AJ, Lipsky M, Mistry P, Pletneva LM, Karp CL, McAlees J, Gioannini TL, and Weiss J, et al (2013) The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature 497:498-502.
42. Ulevitch RJ and Tobias PS (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13:437-457.
43. Wu CC, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, Cottam HB, and Carson DA (2007) Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci USA 104:3990-3995.
44. Yamamoto M, Takeda K, and Akira S (2004) TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 40:861-868.